Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,694 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting.
Alsdorf W, Diels J, Ghilotti F, Mendes J, Hernando T, Cost P, Schecter JM, Lendvai N, Patel N, Triguero A, Ursi M. Alsdorf W, et al. Among authors: patel n. J Comp Eff Res. 2024 Sep;13(9):e240080. doi: 10.57264/cer-2024-0080. Epub 2024 Aug 20. J Comp Eff Res. 2024. PMID: 39162049 Free PMC article. Clinical Trial.
Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison.
Bar N, Diels J, van Sanden S, Mendes J, Hernando T, Burnett H, Cost P, Schecter JM, Lendvai N, Patel N, Ishida T, Er J, Harrison SJ, Lopez-Muñoz N. Bar N, et al. Among authors: patel n. Curr Med Res Opin. 2024 Sep;40(9):1597-1603. doi: 10.1080/03007995.2024.2391112. Epub 2024 Aug 22. Curr Med Res Opin. 2024. PMID: 39129504
Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials.
Yong K, Einsele H, Schecter JM, Roccia T, Deraedt W, Lendvai N, Slaughter A, Lonardi C, Connors K, Qi K, Londhe A, Carson R, Kharat A, Cost P, Valluri S, Mendes J, Pacaud L, Patel N, Florendo E, Dhakal B. Yong K, et al. Among authors: patel n. Eur J Cancer. 2024 Nov 29;215:115157. doi: 10.1016/j.ejca.2024.115157. Online ahead of print. Eur J Cancer. 2024. PMID: 39673835
An umbrella review of meta-analysis to understand the effect of coffee consumption and the relationship between stroke, cardiovascular heart disease, and dementia among its global users.
Gill H, Patel N, Naik N, Vala L, Rana RK, Jain S, Sirekulam V, Jain SM, Khan T, Kinthada S, Patel RB, Nanjundappa A, Siripuram C, Patel U. Gill H, et al. Among authors: patel n. J Family Med Prim Care. 2024 Nov;13(11):4783-4796. doi: 10.4103/jfmpc.jfmpc_654_24. Epub 2024 Nov 18. J Family Med Prim Care. 2024. PMID: 39723018 Free PMC article. Review.
Incidence and predictors of readmission following hospitalization for thoracic disc herniation.
Gerstmeyer J, Avantaggio A, Gorbacheva A, Pierre C, Cracchiolo G, Patel N, Davis DD, Anderson B, Godolias P, Schildhauer TA, Abdul-Jabbar A, Oskouian RJ, Chapman JR. Gerstmeyer J, et al. Among authors: patel n. Clin Neurol Neurosurg. 2024 Dec 19;249:108698. doi: 10.1016/j.clineuro.2024.108698. Online ahead of print. Clin Neurol Neurosurg. 2024. PMID: 39721123
Structural serology of polyclonal antibody responses to mRNA-1273 and NVX-CoV2373 COVID-19 vaccines.
Bangaru S, Jackson AM, Copps J, Fernández-Quintero ML, Torres JL, Richey ST, Nogal B, Sewall LM, Torrents de la Peña A, Rehman A, Guebre-Xabier M, Girard B, Das R, Corbett-Helaire KS, Seder RA, Graham BS, Edwards DK, Patel N, Smith G, Ward AB. Bangaru S, et al. Among authors: patel n. bioRxiv [Preprint]. 2024 Dec 12:2024.12.11.628030. doi: 10.1101/2024.12.11.628030. bioRxiv. 2024. PMID: 39713412 Free PMC article. Preprint.
9,694 results